This ASX 300 healthcare stock is up 48% in 3 days. Broker says buy

It may not be too late to jump on the Neuren rocket.

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Neuren shares have been on fire this week thanks to a major announcement
  • The company's treatment for Rett's Syndrome has been given the thumbs up by the US FDA
  • One leading broker believes it isn't too late to buy shares

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is racing higher again on Wednesday.

In morning trade, the biotech company's shares are up a further 14% to a multi-year high of $11.36.

This means the ASX 300 share has now risen a whopping 48% over the last three sessions.

As you can see below, this has driven the Neuren share price almost 200% higher since this time last year.

Created with Highcharts 11.4.3Neuren Pharmaceuticals PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

Why is this ASX 300 share rocketing this week?

Investors have been buying this ASX 300 share after its treatment for Rett's Syndrome was granted US FDA approval.

This is the first and only approved treatment for Rett Syndrome, which is a rare genetic neurological and developmental disorder that affects the way the brain develops.

The company has a deal in place with its partner Acadia Pharmaceuticals (NASDAQ: ACAD) that could result in significant revenue generation.

This includes royalties of up to 15% of net sales above US$750 million and sales milestone payments of up to US$350 million on total sales above US$1 billion in a calendar year.

Can its shares keep rising?

The good news is that Bell Potter believes the Neuren share price can keep rising even after its stellar gains this week.

This morning, the broker has retained its speculative buy rating with an improved price target of $13.67. This suggests that the ASX 300 share could rise a further 20% from current levels.

Bell Potter commented:

This is a huge success for the company, and we now expect income from trofinetide to come in at up to A$104m plus royalties in 2023. The next potential milestone payment to Neuren would be US$40m (A$61m at an assumed exchange rate of 0.65), payable following the first commercial sale of trofinetide in the United States.

Subsequently, Neuren is eligible to receive double-digit percentage royalties on net sales of trofinetide in North America, plus milestone payments of up to US$350m (A$538m) on achievement of a series of four thresholds of total annual net sales.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »